US2020039931A1PendingUtilityA1

Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b

59
Assignee: JANSSEN SCIENCES IRELAND UCPriority: May 17, 2013Filed: Oct 14, 2019Published: Feb 6, 2020
Est. expiryMay 17, 2033(~6.8 yrs left)· nominal 20-yr term from priority
Inventors:Koen VandyckGeerwin Yvonne Paul HachéStefaan Julien LastDavid Craig McgowanGeert RomboutsWim Gaston VerschuerenPierre Jean-Marie Bernard Raboisson
A61P 31/00A61P 31/20C07D 405/12C07D 207/40C07D 403/12A61K 2300/00A61K 45/06A61K 31/401C07D 207/36A61K 31/4025
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Inhibitors of HBV replication of Formula (ID) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein X, R a to R d and R 4 to R 6 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.

Claims

exact text as granted — not AI-modified
1 - 15 . (canceled) 
     
     
         16 . A compound or pharmaceutically acceptable salt thereof of formula 
       
         
           
           
               
               
           
         
       
     
     
         17 . A compound or pharmaceutically acceptable salt thereof of formula 
       
         
           
           
               
               
           
         
       
     
     
         18 . A compound or pharmaceutically acceptable salt thereof of formula 
       
         
           
           
               
               
           
         
       
     
     
         19 . A pharmaceutical composition comprising a therapeutically effective amount of at least one compound as claimed in claim  1  and a pharmaceutically acceptable carrier. 
     
     
         20 . A pharmaceutical composition comprising a therapeutically effective amount of at least one compound as claimed in claim  2  and a pharmaceutically acceptable carrier. 
     
     
         21 . A pharmaceutical composition comprising a therapeutically effective amount of at least one compound as claimed in claim  3  and a pharmaceutically acceptable carrier. 
     
     
         22 . A method of treating an HBV infection comprising administering a therapeutically effective amount of at least one compound as claimed in claim  1 . 
     
     
         23 . A method of treating an HBV infection comprising administering a therapeutically effective amount of at least one compound as claimed in claim  2 . 
     
     
         24 . A method of treating an HBV infection comprising administering a therapeutically effective amount of at least one compound as claimed in claim  3 . 
     
     
         25 . A pharmaceutical product comprising (a) a compound as claimed in claim  1  and (b) an HBV inhibitor. 
     
     
         26 . A pharmaceutical product comprising (a) a compound as claimed in claim  2  and (b) an HBV inhibitor. 
     
     
         27 . A pharmaceutical product comprising (a) a compound as claimed in claim  3  and (b) an HBV inhibitor.

Join the waitlist — get patent alerts

Track US2020039931A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.